Navigation Links
VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy
Date:11/10/2008

Coadministration of ezetimibe/simvastatin and fenofibrate results in more favorable lipid profile in mixed hyperlipidemia patients

BIRMINGHAM, Ala., Nov. 10 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, Inc., investigators led by Michel Farnier M.D., of Point Medical, Rond Point de la Nation, Dijon, France, have reported beneficial changes in lipoprotein subclasses and LDL particle size using combination therapy. The information could be helpful to physicians because of the known association between abnormal lipoprotein subfractions and increased cardiovascular risk in patients with mixed hyperlipidemia.

Using the Vertical Auto Profile (VAP Test) and S3GGE(TM) particle methods, researchers from the recent study titled VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate discovered that combination therapy achieved greater reductions in cholesterol classes in high-risk patients and resulted in greater positive changes in lipoprotein profile than monotherapy.

Because of the complex nature of mixed hyperlipidemia, medical guidelines recommend treating patients with a combination of lipid-lowering agents. However, clinicians continue to search for the optimal combination to achieve target lipid levels.

"Mixed hyperlipidemia is characterized by an excess of small, dense LDL associated with an increase of triglyceride and a decrease of HDL-cholesterol levels," said Farnier, lead author of the study. "The patients with mixed dyslipidemia frequently require a combination therapy to normalize this atherogenic lipoprotein profile, and in this specific study the combined therapy of ezetimibe/simvastatin and fenofibrate has produced favorable effects on all the atherogenic lipoprotein subclasses."

Details of the 12-week, multi-center, double blind, parallel group study were published in the Journal of Lipid Research. In the study, 611 patient
'/>"/>

SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment
2. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
3. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
7. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
8. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
9. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
10. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
11. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... 27, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... 28 with patients and health care advocates in the ... Disease Day®. Rare Disease Day is dedicated to ... to the special challenges faced by patients with rare ... is proud to stand alongside patients and caregivers representing ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... 11, 2011 Pacira Pharmaceuticals, Inc. ... new data highlighting the pain control and pharmacokinetic ... the company,s lead investigational product for postsurgical pain ... the 2011 Annual Meetings of the American Society ...
... N.Y., Oct. 10, 2011 The Leukemia & ... Apple Co-Founder Steve Jobs from pancreatic cancer. Jobs, death comes ... disease - those of Nobel Laureate Ralph Steinman last week, ... http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) These deaths bring to light ...
... AWAC, an inVentiv Health company, and a leading provider ... solutions, announced today that it has changed its name ... name and organization – unveiled today at the Self-Insurance ... better reflects the company,s expanded solutions, revitalized mission and ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings 4Steve Jobs' Death Highlights Critical Need for New Therapies for Pancreatic Cancer 2AWAC Becomes inVentiv Medical Management™ 2
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... diseases can rival malaria,s ability to kill and cripple. Each year ... and more than a million mostly African children under the ... anniversary of the announcement of the genome sequence of the deadly ... Anopheles . A new book on malaria ...
... shelves until Oct. 2, it has already passed an enviable ... 100 books of all time. And they fit on ... of Genetics at Harvard Medical School and a founding core ... Harvard University, and his team encoded the book, Regenesis: How ...
... as carbon drains but are far from places where greenhouses ... has proposed human, agricultural and livestock waste, such as urine, ... large quantities of carbon dioxide and other greenhouse gases present ... occurring substance. A study published in the Journal of ...
Cached Biology News:New book tells story of 10-year-old malaria project 2New book tells story of 10-year-old malaria project 3Writing the book in DNA 2Writing the book in DNA 3A urine based 'potion' can act as a CO2 absorbent 2A urine based 'potion' can act as a CO2 absorbent 3
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
...
Agarose, Biotechnology grade, 500g...
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
Biology Products: